










OPINION ARTICLE

A community proposal to integrate structural bioinformatics activities in ELIXIR (3D-Bioinfo Community) [version 1; peer review: 1 approved, 3 approved with reservations]

Christine Orengo¹, Sameer Velankar², Shoshana Wodak³, Vincent Zoete⁴, Alexandre M.J.J. Bonvin ⁵, Arne Elofsson ⁶, K. Anton Feenstra ⁷, Dietland L. Gerloff⁸, Thomas Hamelryck⁹, John M. Hancock ¹⁰, Manuela Helmer-Citterich¹¹, Adam Hospital¹², Modesto Orozco¹², Anastassis Perrakis ¹³, Matthias Rarey¹⁴, Claudio Soares¹⁵, Joel L. Sussman¹⁶, Janet M. Thornton¹⁷, Pierre Tuffery ¹⁸, Gabor Tusnady¹⁹, Rikkert Wierenga²⁰, Tiina Salminen²¹, Bohdan Schneider ²²

¹Structural and Molecular Biology Department, University College, London, UK

²Protein Data Bank in Europe, European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, UK

³VIB-VUB Center for Structural Biology, Brussels, Belgium

⁴Department of Oncology, Lausanne University, Swiss Institute of Bioinformatics, Lausanne, Switzerland

⁵Bijvoet Center, Faculty of Science – Chemistry, Utrecht University, Utrecht, 3584CH, The Netherlands

⁶Science for Life Laboratory, Stockholm University, Solna, S-17121, Sweden

⁷Dept. Computer Science, Center for Integrative Bioinformatics VU (IBIVU), Vrije Universiteit, Amsterdam, 1081 HV, The Netherlands

⁸Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, L-4367, Luxembourg

⁹Bioinformatics center, Department of Biology, University of Copenhagen, Copenhagen, DK-2200, Denmark

¹⁰ELIXIR Hub, ELIXIR, Hinxton, UK

¹¹Department of Biology, University of Rome Tor Vergata, Rome, I-00133, Italy

¹²Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, 08028, Spain

¹³Netherlands Cancer Institute and Oncode Institute, Utrecht, The Netherlands

¹⁴ZBH - Center for Bioinformatics, Universität Hamburg, Hamburg, D-20146, Germany

¹⁵Instituto de Tecnologia Química e Biológica Antonio Xavier, Universidade Nova de Lisboa, Lisbon, Portugal

¹⁶Department of Structural Biology, Weizmann Institute of Science, Rehovot, 76100, Israel

¹⁷European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, UK

¹⁸Ressource Parisienne en Bioinformatique Structurale, Université de Paris, Paris, F-75205, France

¹⁹Membrane Bioinformatics Research Group, Institute of Enzymology, Budapest, H-1117, Hungary

²⁰FBMM, Biocenter Oulu, University of Oulu, Oulu, Finland

²¹Structural Bioinformatics Laboratory, Åbo Akademi University, Turku, FI-20500, Finland

²²Institute of Biotechnology of the Czech Academy of Sciences, Vestec, CZ-25250, Czech Republic

v1 First published: 22 Apr 2020, 9(ELIXIR):278
<https://doi.org/10.12688/f1000research.20559.1>

Latest published: 22 Apr 2020, 9(ELIXIR):278
<https://doi.org/10.12688/f1000research.20559.1>

Abstract

Structural bioinformatics provides the scientific methods and tools to analyse, archive, validate, and present the biomolecular structure data

Open Peer Review

Reviewer Status    

Invited Reviewers

generated by the structural biology community. It also provides an important link with the genomics community, as structural bioinformaticians also use the extensive sequence data to predict protein structures and their functional sites. A very broad and active community of structural bioinformaticians exists across Europe, and 3D-Bioinfo will establish formal platforms to address their needs and better integrate their activities and initiatives. Our mission will be to strengthen the ties with the structural biology research communities in Europe covering life sciences, as well as chemistry and physics and to bridge the gap between these researchers in order to fully realize the potential of structural bioinformatics. Our Community will also undertake dedicated educational, training and outreach efforts to facilitate this, bringing new insights and thus facilitating the development of much needed innovative applications e.g. for human health, drug and protein design. Our combined efforts will be of critical importance to keep the European research efforts competitive in this respect.

Here we highlight the major European contributions to the field of structural bioinformatics, the most pressing challenges remaining and how Europe-wide interactions, enabled by ELIXIR and its platforms, will help in addressing these challenges and in coordinating structural bioinformatics resources across Europe. In particular, we present recent activities and future plans to consolidate an ELIXIR 3D-Bioinfo Community in structural bioinformatics and propose means to develop better links across the community. These include building new consortia, organising workshops to establish data standards and seeking community agreement on benchmark data sets and strategies. We also highlight existing and planned collaborations with other ELIXIR Communities and other European infrastructures, such as the structural biology community supported by Instruct-ERIC, with whom we have synergies and overlapping common interests.

Keywords

structural bioinformatics, biomolecular structure, protein structure, nucleic acids structure, ELIXIR, Instruct-ERIC

version 1	1	2	3	4
22 Apr 2020	✓	?	?	?
	report	report	report	report

- 1 **Sjoerd Jacob De Vries**, RPBS platform, Paris, France
Isaure Chauvot de Beauchene , University of Lorraine, Nancy, France
- 2 **Silvio Tosatto** , BioComputing Laboratory, Padova, Italy
- 3 **Roland L. Dunbrack** , Fox Chase Cancer Center, Philadelphia, USA
- 4 **Andras Fiser** , Albert Einstein College of Medicine, The Bronx, USA

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the **ELIXIR** gateway.

Corresponding authors: Christine Orengo (c.orengo@ucl.ac.uk), Bohdan Schneider (bohdan.schneider@gmail.com)

Author roles: **Orengo C:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Velankar S:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Wodak S:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Zoete V:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Bonvin AMJJ:** Writing – Review & Editing; **Elofsson A:** Writing – Review & Editing; **Feenstra KA:** Writing – Review & Editing; **Gerloff DL:** Writing – Review & Editing; **Hamelryck T:** Writing – Review & Editing; **Hancock JM:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing; **Helmer-Citterich M:** Writing – Review & Editing; **Hospital A:** Writing – Review & Editing; **Orozco M:** Writing – Review & Editing; **Perrakis A:** Writing – Review & Editing; **Rarey M:** Writing – Review & Editing; **Soares C:** Writing – Review & Editing; **Sussman JL:** Writing – Review & Editing; **Thornton JM:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Tuffery P:** Writing – Review & Editing; **Tusnady G:** Writing – Review & Editing; **Wierenga R:** Writing – Review & Editing; **Salminen T:** Writing – Review & Editing; **Schneider B:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by ELIXIR Europe

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Orengo C *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Orengo C, Velankar S, Wodak S *et al.* **A community proposal to integrate structural bioinformatics activities in ELIXIR (3D-Bioinfo Community) [version 1; peer review: 1 approved, 3 approved with reservations]** F1000Research 2020, 9(ELIXIR):278 <https://doi.org/10.12688/f1000research.20559.1>

First published: 22 Apr 2020, 9(ELIXIR):278 <https://doi.org/10.12688/f1000research.20559.1>

List of abbreviations

3D-Bioinfo: name of the ELIXIR Community of structural bioinformatics

BioExcel: Center of excellence for biomolecular research

Biomedinfra: authentication and authorisation infrastructure (ELIXIR AAI) of ELIXIR Finland

CAMEO: Continuous Automated Model Evaluation

CAPRI: community-wide experiment on the comparative evaluation of protein-protein docking for structure prediction

CASP: critical Assessment of protein structure prediction

ChEMBL: a manually curated database of bioactive molecules with drug-like properties

COOT: crystallographic object-oriented toolkit, a graphics for refinement of experimental biomolecular structures

COST: (European) cooperation in science and technology

EMDB: Electron microscopy data bank

ELIXIR: intergovernmental organisation that brings together life science resources from across Europe

EM, cryo-EM: electron microscopy, cryo-electron microscopy

EOSC-Hub: European Open Science Cloud

EU-OPENSREEN: integrates high-capacity screening platforms throughout Europe

FAIR: data which meet principles of findability, accessibility, interoperability, and reusability

FARFAR: fragment assembly of RNA with full-atom refinement

FARNA,: fragment assembly of RNA

Instruct, Instruct-ERIC: pan-European research infrastructure in structural biology

MD: molecular dynamics

microED: electron micro-crystallography

MMB: MacroMolecularBuilder. A program suite for macromolecular modelling

MX macromolecular X-ray crystallography

NMR: nuclear magnetic resonance, a spectroscopic method

OpenEBench: infra-structure designed to establish a continuous automated benchmarking system for bioinformatics

PDB: Protein data bank

PDBe-KB: Protein data bank in Europe - knowledge base

PDB-Redo: procedure to optimise crystallographic structure models

Phenix: software suite for the automated determination of molecular structures

PHYRE: automatic fold recognition server for predicting the structure and/or function of the protein sequence

Proteopedia: wiki and 3D encyclopedia of proteins and other biomolecules

Pubchem: database of chemical molecules and their activities

Refmac: program for refinement of experimental structures of biomolecules

RNA Puzzles: collective experiment for blind RNA structure prediction

SAXS: small angle X-ray scattering

SBDD: structure-based drug design

Swiss-model: structural bioinformatics web-server dedicated to homology modelling of 3D protein structures

TeSS portal: ELIXIR's training portal

UniProt: Universal protein resource, a comprehensive resource for protein sequence and annotation data

Web-Beagle: web server for the alignment of RNA secondary structures

Major European contributions in structural bioinformatics

Structural bioinformatics is a well-established scientific activity, which started in the 1970s following the establishment of the Protein Data Bank¹ which provides open access to macromolecular structure models. **Figure 1** illustrates major themes in structural bioinformatics. Structure data can give deeper insights into the mechanism of proteins, the functions of biomolecules (proteins, nucleic acids, carbohydrates, lipids, etc.) and their interactions with each other and with chemical modulators of their functions (inhibitors, activators, co-factors, etc.). This enables the design of new experiments to study the function of macromolecules as well as rational design of proteins and drugs, to modify their function and properties.

Structure models are experimentally determined by macromolecular X-ray crystallography (MX) and small angle X-ray scattering (SAXS), nuclear magnetic resonance spectroscopy (NMR), or cryo-electron microscopy (EM). The technological developments in MX in the previous decade, largely catalysed by the structural genomics initiatives and the on-going revolution in the field of cryo-EM, are expanding the volume of structural data both quantitatively and qualitatively (see **Figure 2**). European structural bioinformatics groups have played a crucial role in the development of methods to validate this data^{2,3} and the world-wide adoption of these tools by the structural biology community. They have also initiated collaborations and joint activities between structural bioinformaticians and structural biologists, expanding recently to meet the need to develop




Figure 1. Schematic illustrating major themes in structural bioinformatics. Top row – protein structure validation, protein structure comparison and classification, protein ligand interactions, nucleic acid structures, protein-protein interactions and complexes; middle row – protein structure prediction, prediction of protein interactions, protein structure dynamics; bottom row – integration of protein structure and sequence to predict functional sites and effects of genetic variations, exploiting protein structure annotations for comparative genome studies.

tools and validation protocols for structures determined using new techniques such as EM (cryoEM, microED) and Integrative/hybrid methods.

European bioinformatics groups have also been at the forefront of efforts to compare protein structures and characterise their features in order to understand the underlying principles of protein structure and function⁴ and thereby promote both fundamental and translational research. For example, characterisation of protein binding pockets provided vital information for rational drug design. Europe also pioneered the establishment of comprehensive structure-based protein classifications^{5,6} giving structural insights into protein evolution and European structure-based tools have facilitated enzyme reaction mechanism studies by chemists and biochemists.

Another major European activity, the prediction of protein structures from amino acid sequences, started in the late 1980s. European groups were amongst the first to predict protein secondary and tertiary structure for soluble and membrane associated proteins. Additionally, some of the most critical contributions

to building protein 3D models from structural templates of homologous proteins, happened in Europe in the 1990s^{7,8}, together with the development of methods for assessing model quality. European bioinformatic groups have also provided key solutions for the hardest task of *de novo* prediction of protein spatial structures⁹. Furthermore, European groups have made seminal contributions to the development of methods for modelling the 3D structure of protein complexes¹⁰, a very difficult problem, which is centre stage for today's molecular biology. These activities have been further expanded in the field of multi-scale modelling where a wide variety of experimental and bioinformatics data are integrated into the modelling process. Importantly European groups have made major contributions to initiatives assessing the performance of structure prediction and protein docking methods (see reviews 11–13).

European research groups contributed significantly to the field of RNA bioinformatics, setting standards in RNA structure predictions, modeling, and data format^{14,15}. In particular, the RNA-Puzzles experiment for evaluation of RNA structure prediction methods, and a series of associated workshops




Figure 2. (a) Total number of PDB entries and number of entries for each major experimental type. (b) Number of nuclear magnetic resonance (NMR) and electron microscopy (EM) entries deposited per year. (c) Number of new entries deposited each year and number of new proteins (UniProt accession) added per year.

have been introduced in Europe, attracting the top groups world-wide^{16,17,18}.

Protein function is strongly related to molecular recognition of small molecules such as substrates, inhibitors, or signaling compounds and many European groups have been active in this area over the last 50 years^{19,20,21} and remain major players in the field. Europe also has an exemplary track record in developing molecular dynamics (MD) simulation techniques and applying them to investigate dynamic properties of protein systems, functionally important conformational transitions in proteins, as well as folding and unfolding reactions^{22,23,24}, providing crucial insight into dynamics aspects that are notoriously difficult to capture by experimental approaches.

Protein structural data and functional residue annotations also inform protein engineering, another important activity with significant European representation. For instance, the discovery of canonical conformations in antibody variable domains²⁵ spurred the development of the first methods for accurate structure prediction in antibodies²⁶. Other biocomputational methods have been important for enzyme engineering. Such contributions by European bioinformaticians have transformed the face of protein engineering and were the basis for establishing major biotechnological companies for developing new research and clinical tools.

Major challenges that 3D-Bioinfo will help to address

Improvements in structure prediction opens up huge possibilities including understanding the effects of disease causing mutations, and provides an essential platform for almost all future translational efforts including developing novel drugs. Furthermore, international initiatives (i.e. CASP²⁷, CAMEO²⁸ and CAPRI^{29,30} for assessment of the prediction of protein structures and complexes have driven the field by independently

validating methods and highlighting innovations that increase performance. However, many challenges still exist. It remains computationally expensive to build 3D models on a proteome-wide scale. Furthermore, prediction methods are still error prone. It is therefore important to increase coverage and confidence measures by consolidating results from multiple methods. ELIXIR is already supporting some Europe-wide collaborative initiatives. For example, a recent implementation study links several major structure prediction and annotation resources (SWISS-MODEL³¹, PHYRE³², GenTHREADER³³, Fugue³⁴, SUPERFAMILY³⁵, CATH-Gene3D³⁶) with ELIXIR Core Resources, PDBe³⁷ and InterPro³⁸ to increase the coverage and reliability of predicted protein structure data (see Figure 3).

Structural bioinformatics tools link sequence and structure data to predict protein functional sites. As for protein structure prediction, integration of data on sites predicted by different methods will increase both coverage and accuracy. In this context, new initiatives like the PDBe Knowledgebase (PDBe-KB) are integrating data from multiple European groups allowing easy access, development of meta-predictors and common benchmarking to improve accuracy. Since some disease-associated genetic variations result in modifications of protein residues in or near functional sites, these initiatives provide a natural link with the ELIXIR Human Rare Disease Community.

Recent and future technological challenges of structural biology such as EM, serial crystallography, fragment screening, bio-SAXS, time-resolved structural methods, and techniques of integrated biology in general, are important areas that can be addressed by structural (3D) bioinformatics, albeit always in close collaboration with structural biology research groups. Optimal data formats, FAIRness³⁹ of the data, interoperability of the data and software tools are serious issues that




Figure 3. The coverage of protein sequences from selected model organisms with structural annotations provided by the Genome3D resource.

require close collaboration between structural biologists and bioinformaticians.

With regard to prediction of protein-ligand interactions, protein/drug design, and modelling of dynamic properties of proteins and their interactions, much work remains to be done in benchmarking of methods and better integration of methods and data. 3D-Bioinfo will endeavour to facilitate collaborations and new initiatives in these areas.

Goals of 3D-BioInfo

The major goals of 3D-Bioinfo will be to increase interoperability between resources by developing and promoting data standards, integrating data where appropriate and developing robust benchmarking strategies for prediction algorithms (e.g. protein structures, complexes, ligand/drug docking). We will also develop better visualization frameworks for protein and nucleic acid structures and work closely with the structural biology community and initiatives such as Instruct-ERIC to develop improved validation metrics for nucleic acid structures, an important area, which is currently underdeveloped.

The 3D-Bioinfo major goals can be summarized as follows:

- Promote and develop data standards to drive data integration
- Plan the long-term sustainability for key computational tools and data resources
- Drive the integration of resources and tools for analysis of structural data
- Develop robust standard methods for benchmarking and validating prediction tools
- Facilitate the access of tools requiring high compute power to the appropriate facilities
- Improve integration of structural data with other quantitative biological data
- Pool and expand the available training and outreach material in structural bioinformatics.

Links between 3D-Bioinfo and the wider European research environment

The structural bioinformatics community forms an indispensable interface between producers of structural data and their users. There are already several ELIXIR endorsed node resources/servers (SWISS-MODEL³¹, Phyre³²) and Core Data Resources (PDBe³⁷, CATH³⁶) in 3D-Bioinfo.

[European groups participating in 3D-Bioinfo](#) have been involved in European networks providing derived structural data and analysis tools to biologists (e.g. InteGr8, IMPACT, Biosapiens, Instruct-ERIC, BioExcel, Biomedinfra, EU-OPENSOURCE, EOSC-Hub) and COST Actions (e.g. CA15135 - Multi-target paradigm for innovative ligand identification in the drug discovery process; CM1306 - Understanding Movement and Mechanism in Molecular Machines, [COST Action BM1405](#) (CA17139 EUTOPIA (EUropean TOPology Interdisciplinary Action), WP3 Entangled and Self-entangled Proteins).

Other international collaborations include the Protein Structure Initiative (PSI) for structural genomics. A significant fraction of the tools/resources provided by ELIXIR nodes relates to structural bioinformatics and the combined resources receive hundreds of thousands of web-accesses/month from the wider global research community.

3D-Bioinfo Executive and Steering Committees

The 3D-Bioinfo Community includes leading figures in the field of structural bioinformatics across Europe. It was initiated in March 2018 with the formation of a Steering Committee and an Executive Committee comprising representatives from 16 ELIXIR nodes. These members actively sought further participants from within their nodes, covering a wide spectrum of skills and needs (see [European groups participating in 3D-Bioinfo](#)). They are responsible for the development and sustainable operation of complex tools ranging from databases to infrastructures promoting interoperability between multiple areas of research that rely on the reusability of structural data provided by the structural biology community (e.g. as represented by Instruct-ERIC).

Description of the launch meeting

3D-BioInfo was launched at a meeting in Basel, September 2018, with 70 participants from 15 European countries providing their input. In addition to presentations from committee members on the proposed 3D-Bioinfo Activities, representatives of the five ELIXIR platforms on data, tools, interoperability, compute and training, described their activities. John Hancock also gave a presentation as Coordinator of ELIXIR Communities and representative of the ELIXIR hub. Additionally, 19 ‘flash talks’ were given by European research groups interested in contributing to one or more of the proposed 3D-Bioinfo activities and/or to joint activities with the ELIXIR platforms. Organisers of related ELIXIR communities (proteomics, intrinsically disordered proteins and human copy number variation) gave presentations indicating possible areas of future collaboration. There were also oral contributions from representatives of other European ESFRI initiatives like Instruct-ERIC and BioExcel, again highlighting synergies and possible collaborations. Posters from many research groups, keen to participate in 3D-Bioinfo, were presented at the meeting highlighting their possible contributions and an interactive session was held allowing participants to discuss the proposed Activities and suggest future Activities. Participants also discussed ideas for interaction with the ELIXIR platforms.

Activities and action plans prioritized by 3D-Bioinfo

Following their formation in March 2018, the 3D-Bioinfo Executive and Steering Committees held regular conference calls to determine the highest priority areas, which would become the main Activities to be first undertaken by the community. These 3D-BioInfo Activities, outlined below, were further discussed and refined at the launch meeting, and involve multiple participating groups across the nodes.

Structural Bioinformatics is well established, as the field began more than 40 years ago following the establishment of the protein structure databank in the 1970s, so most of these

Activities represent mature areas of research, some of which had already received sustained node funding to develop their tools and resources. Each Activity will have the major goals, listed above, as the core of their mission. They are being coordinated via regular conference calls and are each evolving specific tasks. Below we detail, the specific thematic aims of each Activity and highlight the planned interactions with the ELIXIR platforms.

Activity I: Infrastructure for FAIR structural and functional annotations

Coordinator: Sameer Velankar. The Protein Data Bank (PDB) and the Electron Microscopy Data Bank (EMDB) both follow the FAIR principles, thus enabling many niche data resources to derive added value annotations from the archived structural data, such as structure domain classifications, information on ligand- and macromolecule binding sites and effects of mutations on structure and function. However, a lack of coordination between these specialist data resources has prevented the creation of data standards and uniform data access mechanisms, consequently reducing the impact of these valuable data.

The proposed Activity will address these omissions by further developing the PDBe Knowledge Base (PDBe-KB) – a community-driven data resource for structural and functional annotations that places structural data in its biological context. PDBe-KB increases the visibility and interoperability of niche data resources by collating minimally required common structure-based annotation data in a standardized data exchange format and by enabling comparisons between specific types of annotations obtained from different software tools.

The initial focus of this Activity will include three major goals: i) continue to expand the scope of integrating known and predicted functional site annotations with PDBe-KB; ii) integration of annotations concerning the impacts of disease-associated variants on structure and function in PDBe-KB; and iii) integration of predicted protein structure data via existing model archives by establishing a federated infrastructure for access (3D-Beacons).

Identifying additional predicted or manually curated annotations that could further enrich the integrated data of PDBe-KB: The lack of data standards and fragmented nature of specialist data resources is a barrier to the FAIR principle. We will bring together the community experts to define data standards for different types of annotations and integration of these annotations using a community-driven data exchange format will facilitate finding, accessing and reusing sparse annotations in an interoperable manner. Activity I will ensure that PDBe-KB will be an effective platform for the collaborating partners to share and compare their value-added, structure-derived annotations. Furthermore, we will continue to identify gaps in coverage of the various types of annotations in PDBe-KB and bring together community experts to fill in those gaps. The workshops will also facilitate the development and testing of new methods by providing valuable, standardized benchmarking data sets.

Integration of annotations related to the impacts of disease-associated variants on structure and function: By bringing together developers of specialist data resources and scientific software tools that can provide information on the effects of amino-acid variation on structure and function, we will establish data standards to represent these data. The data standards will support integration of these annotations in PDBe-KB with particular emphasis on the effect of disease-related mutations on conformational stability. Compiling and integrating these annotations will be highly beneficial when investigating naturally occurring variations, and when used together with all the other types of integrated annotations it may facilitate development of better tools ultimately benefiting the wider biomedical research community.

Integrating predicted protein structure models (3D-Beacons): Taking advantage of the highly interconnected data of PDBe-KB will allow the transfer of valuable annotations to structural models based on sequence- or structural similarity when experimentally determined structural data is unavailable. Development of 3D-Beacons infrastructure by incorporating structural models from existing European archives (e.g. SWISS-MODEL³¹, Genome3D⁴⁰) and other international resources (e.g. MODBASE⁴¹ and Gremlin⁴²) will facilitate an increase in the coverage of structure data in the sequence space. The PDBe-KB data alongside the predicted structure models will potentially allow the scientific community to gain valuable insights regarding the biological context.

The focused activities will take advantage of the existing PDBe-KB infrastructure, and will include developing community-driven data standards and a uniform data access mechanism in addition to novel, portable and distributed web-based visualisation components. Activity I will build on existing collaborations involving five ELIXIR nodes (UK, Italy, Spain, Czech Republic, Belgium).

Activity II: Open resources for sharing, integrating and benchmarking software tools for modelling the proteome in 3D

Coordinator: Shoshana Wodak. Activity II is about empowering the scientific community to extend the current information on protein 3D structures, protein interactions and assemblies, and extract knowledge from this information by using computational and bioinformatics methods, and integrating biological data from different sources. Its initial focus will be on software tools and benchmark datasets for modeling the 3D structures and conformational flexibility of proteins and protein assemblies, and on community-wide benchmarking activities that advance the field. This focus will subsequently be broadened to include other areas where 3D modelling of proteins and their interactions is most impactful. The following specific aims will be pursued.

Extend the content of OpenEBench by adding a knowledge base integrating software tools for modeling the 3D structure of proteins, protein complexes and assemblies. A variety of software tools are available for modeling protein structures and protein complexes by exploiting available protein sequence

data and information on known structures in the Protein Data Bank (PDB). Exploiting these data successfully involves integrating the appropriate set of tools for the problem at hand. The Community will tap into OpenEBench a knowledge portal fostering benchmarking in the life sciences domain and an important component of the ELIXIR Tools Platform, with exemplary datasets of CAMEO and CAPRI already present. The extension will include workflows and guidelines to software tools and servers for modeling protein structures and complexes, based on known structures (templates) in the PDB. More specifically tools for template-based modeling of protein assemblies, and for Integration of template-based modeling of individual subunits, with protein-protein and protein-peptide docking servers developed by members of the CAPRI community. For a more in-depth understanding of the resources please refer to the [CAPRI](#) and [CAMEO](#) websites. 3D-Bioinfo will build on these efforts and take them to the next level.

Develop a set of standard freely available tools for evaluating the quality of 3D models of proteins and protein complexes.

Evaluating the quality and accuracy of 3D models of proteins and protein complexes plays a crucial role in evaluating the performance of molecular modeling methods, and helping methods developers to optimize their procedures. Furthermore, to effectively compare the performance across methods, agreed upon standard quality measures and evaluation protocols are necessary, as implemented for single protein models by CAMEO modeling (3D), the CAMEO Quality Estimation (QE) category and for protein – protein complexes by the CAPRI community. Major goals will include:

- 1) Full automation of the CAPRI quality assessment procedures for models of protein-protein and protein-peptide complexes, and larger assemblies and making them widely accessible online and for download,
- 2) Integration of the CAPRI and CAMEO model quality assessment tools,
- 3) Making the integrated tools available as open software through a community repository (e.g. on GitHub, building on the [GitHub established by the CAPRI community](#)).

Develop a one-stop-shop of benchmark datasets for testing and evaluating methods for generating scoring, and ranking models of protein complexes.

The availability of appropriate benchmark datasets has been crucial for the development of protein modeling procedures at all levels. Protein docking benchmarks, which assemble high resolution 3D structures of selected sets of known protein complexes and their components^{43,44,45} as well as their experimentally measured affinities^{46,47}, have been widely used for benchmarking methods for protein-protein docking, and for predicting and scoring protein interaction interfaces. The OpenEBench project within ELIXIR-EXCELERATE (OpenEBench.bsc.es⁴⁸) has established a transparent data model that allows not only the sharing of benchmarking

datasets, but also analyzing and comparing the performance of different prediction algorithms on these datasets.

OpenEBench will thus foster a collection of benchmark datasets relevant to the field of modeling the 3D structure of monomeric, homo-oligomeric and heteromeric protein complexes, extending to proteins - peptide and protein - nucleic acid interactions. It will include: 1) [protein docking and affinity benchmark datasets](#) developed by members of the CAPRI community, 2) datasets comprising all the predicted models of protein assemblies submitted to CAPRI and CASP blind prediction challenges, following the examples of the Score-Set⁴⁹ derived from predicted models submitted to CAPRI, 3) a dynamic benchmark for protein complexes beyond binary interactions, considering different difficulty levels (See [DynBench3D](#)⁵⁰). In addition a mechanism will be developed for users to contribute datasets⁵¹, following well-defined community-approved standards such as the mmCIF based modeling extension developed in collaboration with the RCSB within the macromolecular [ModelArchive.org](#) project.

Develop the infrastructure to manage the CAPRI challenge, in coordination with CAMEO.

For CAPRI: Develop automated registration and submission procedures (including automated validation of compliance with standard format), as well as tools for accessing and navigating target information, predicted models and prediction results on the CAPRI website. Work on these tasks is currently underway at CAPRI-EBI, but further support is needed to complete it. For CAMEO: CAMEO is currently adding a new category for heteromeric complex modeling. We propose a close collaboration with CAPRI concerning the prediction and scoring applied during fully automated evaluations.

Develop a knowledge portal to user-friendly bioinformatics and computational tools for modeling conformational flexibility of proteins.

Adequate modeling of conformational changes is currently a major bottleneck in protein assembly modeling. To foster progress an important first step would be to develop a knowledge portal offering the modeling community at large, workflows and guidelines to various available computational and bioinformatics tools for modeling conformational flexibility. We will use the bio.tools registry established by the ELIXIR Tools Platform as infrastructure for this. bio.tools has tags, one of which is structure prediction, but it should be possible to add more customized tags. With such tools playing an important role in modeling intrinsically unstructured proteins, collaborations with the ELIXIR Community on protein intrinsic disorder on topics of common interest will be undertaken.

Activity III: Protein-ligand interactions

Coordinator: Vincent Zoete. The biological activity of biomacromolecules is often linked to the three-dimensional recognition and binding of small molecules such as substrates, activators or inhibitors. Indeed, a large fraction of drugs are ligands

targeting macromolecules like enzymes, receptors, transporters or ion channels. Consequently, important efforts have been dedicated to develop computer-aided drug design (CADD) and notably structure-based drug design (SBDD) approaches over the last decades, contributing significantly to the design of small molecules of therapeutic interest.

The field of drug discovery and development will face several challenges in the future. The on-going needs in medicinal chemistry prompts a dramatic demand for new molecular entities and the exploitation of chemical spaces that are yet unexplored. Despite important progress over the last few decades, toxicity issues remain a problem for small compounds. This has to be addressed through increased specificity, but also via a better characterization of the possible targets and the anticipation of multiple off-target effects. Toxicogenomics, pharmacogenomics, and phenotypic screening data should be collected, organized and disseminated to get a clearer overview of biomacromolecule-ligand interactions, and to ultimately predict *in silico* the poly-pharmacology of the compounds. New target classes are also emerging, beyond the usual well-defined binding pockets, including among others the interaction of proteins with other proteins, nucleic acids, lipids or sugars. These additions in the target classes are mirrored by the use of new classes of ligands, including peptides and macrocyclic compounds. These new types of target-ligand interactions will foster the development of novel *in silico* approaches, which will require new algorithms and thorough evaluations of their descriptive and predictive capacities.

Among other *in silico* technologies, structure based drug design (SBDD) methods remain in great need of comprehensive evaluations of their performance and domain of applicability. In particular, there is a need for improved docking and scoring methods. Although protein-ligand complexes can be predicted for small ligands and almost rigid proteins, large, flexible molecules like peptides or macrocycles and proteins with flexible binding regions are still very difficult to handle. The reliable prediction of the binding free energy of a protein-ligand complex also remains a major challenge. Better methods making use of precise chemical models, modern optimization techniques and innovative scoring approaches are still much needed but must be accompanied by comprehensive and rigorous evaluations of their performance and domain of applicability. This should go hand in hand with the creation of processing pipelines for the proper use of structural data, and of standardizing tools for IO.

The efficiency of SBDD tools often depends on molecular/physicochemical properties such as the charge, polarity or size of the protein binding site and ligand, as well as on the target class of the biomacromolecule or the chemical class of the ligand. To address this, benchmark sets should clearly list and quantify these different properties for each complex with suitable descriptors, transparent for the user community. For Activity III, we plan the following goals:

Creation of benchmark datasets to assess structure-based drug design tools. Benchmarking studies performed so far,

including those carried out in the CSAR⁵² or D3R Grand Challenge⁵³ which focus on compound series consistently measured within one lab/institute - rely on datasets of limited size and diversity, precluding large-scale, FAIR comparisons of their performance, especially as a function of ligand and binding site properties. Activity III will therefore involve:

1) Building benchmark datasets, extracted from the PDB and curated, for assessing SBDD tools on a large-scale, under well-defined FAIR conditions, thereby complementing efforts such as the D3R grand challenges. A particular effort will be devoted to collecting complexes involving peptides and macromolecules.

2) Quantifying different properties (e.g. charge, polarity, size, flexibility of the binding site and ligand etc.) for each entry in the benchmark, to enable evaluation of SBDD tools as a function of these properties.

3) Developing links to other databases and standardizing the retrieved data to complement the information provided for each protein-ligand complex in the benchmark sets; notably, collecting information on ligands in collaboration with PDBe-KB, and associating complexes with reliable binding affinity data using databases like ChEMBL⁵⁴ and Pubchem⁵⁵.

4) Adding information on the non-bioactive conformations of ligands to standardize the comparison of docking calculations starting from such geometries.

5) Adding information on experimentally determined non-active compounds (taken e.g. from ChEMBL⁵⁴) to be used as negative examples for testing virtual screening procedures.

Dissemination and promotion of the benchmark datasets and results. Benchmark datasets will be made publicly available by following Open Access and FAIR principles via a collaboration with the OpenEBench project within ELIXIR EXCELERATE. The latter will also allow the sharing of benchmarking results, and comparing the performance of different prediction algorithms under FAIR conditions. Preferred standardized benchmark workflows and protocols will be published, to guarantee an objective comparison of different tools. Researchers will be encouraged to evaluate their preferred sets of SBDD approaches using the above-mentioned standardized benchmarking workflows and protocols, and to report their results. We will collect the latter and provide them to the community. This activity will be of major value to Pharma and Biotech researchers, who acknowledge the importance of standard benchmarking protocols.

Biomacromolecule-ligand interactions for every scientist, educational aspects. Despite significant interest in using modelling approaches among life scientists, the use of biomacromolecules structures in molecular design largely remains a domain for experts. However, complex data preparation and association could be largely automated resulting in easier-to-use software and substantially lowering the usage barrier for life scientists. By encouraging the development of

tutorials guiding the application of modelling and the interpretation of the achieved results, we will endeavour to open the world of structure-based modelling to the broader life science community.

Activity IV: Tools to describe, analyse, annotate, and predict nucleic acid structures

Coordinator: Bohdan Schneider. The ultimate goal and vision of Activity IV is to encourage development and use of software tools to describe, analyse, annotate, and predict nucleic acid (NA) structures. The availability and sophistication of tools dealing with various hierarchies of the nucleic acid structure lag behind the tools used to explore protein structures and this situation must be remedied. In particular, standards are needed for initial model building and refinement of nucleic acid molecular structures. This task has become urgent as new techniques, including, but not limited to cryo-EM, are generating experimental data on 3D structures containing RNA and DNA molecules, such as ribosomes, spliceosomes, polymerase assemblies, and histone complexes, faster than ever before. The modelling of large nucleic acid molecules into low-resolution electron densities is particularly challenging. The RNA structural bioinformatics community has provided prototype tools, with which to model RNA and RNA-protein complexes based on experimental data, but these tools are currently not compatible with community-wide standards describing RNA and DNA conformational space and geometry at the local (nucleotide or dinucleotide) levels.

Therefore, efforts need to be directed towards formulating community-accepted benchmarks that integrate the different levels of nucleic acid structure descriptions, and more generally to improving software tools that describe, analyse, annotate, and model nucleic acid structures. To enable these developments, Activity IV will focus on the following specific goals:

- 1) Cataloguing software tools for building nucleic acid models based on their sequences alone as well as for modelling their 3D structures using experimental data, and facilitate integration of these tools.
- 2) Coordinating the unification of the existing NA geometry standards and formulate specifications for missing standards.
- 3) Developing benchmarks dataset for evaluating the quality of predicted or experimentally determined NA structures.

To limit the redundancy and increase the synergy between the methods, databases, web services, and other tools, we plan to continuously update the catalogue of software tools developed by the RNA tools and software consortium, extend these tools to DNA structures and enable integration of emerging tools. These efforts will build on existing ontologies while preserving consistency with new extensions.

This integration effort will require a significant level of interoperability between data exchange protocols and software, which will be implemented following FAIR principles.

Dealing with software to solve, model, and refine NA structures based on the experimental data will require a close collaboration with experimentalists. Hence joining forces with Instruct-ERIC will be essential, for reaching all the stated goals, including the development of benchmarking tools and standards.

We list a few examples of steps, which could assist useful integration of the existing tools:

- 1) Adding links from existing servers to other tools, especially those linking 2D and 3D structure prediction. The RNA Tools and Software Consortium have already recapitulated methods for RNA secondary structure prediction and to some extent RNA 3D tools. The RNA Puzzles community of RNA structural bioinformaticians^{16,17,18} has developed a set of tools for linking 2D and 3D structures, software for RNA 3D structure model evaluation also exists, e.g. RASP⁵⁶ or MacroMoleculeBuilder, MMB⁵⁷.
- 2) Unifying the libraries of RNA/DNA dinucleotide fragments based on the analysis of experimental structures^{58,59} and trinucleotide fragments⁶⁰. Ultimately, the community should reach a consensus on what is the meaning of “preferred”, “allowed” and “wrong” conformers in analogy with the use of these terms in the Ramachandran plot.
- 3) Integrating and benchmarking methods dealing with RNA structures, e.g. SimRNA⁶¹, RNAComposer⁶², MMB⁵⁷, FARNA/FARFAR⁶³, Web-Beagle⁶⁴.
- 4) Strengthening the collaboration with developers of the main experimental nucleic acid structure determination software tools (e.g. REFMAC⁶⁵, COOT⁶⁶, Phenix⁶⁷, PDB-REDO⁶⁸) to encourage consistent handling of NAs.

The goals of Activity IV are quite ambitious, and their implementation will require close and friendly collaboration of all research teams willing to participate; including the teams involved in this Activity, and other teams active in the field. The teams not involved in Activity IV will be encouraged to join. Successful completion of the stated goals will also depend on the close collaboration of scientists grouped under other infrastructure projects in Europe and beyond. New tools, standards and benchmarks developed for NA validation will be communicated to the experimental structural biology community, mainly Instruct-ERIC but also EuroBioImaging, to ensure consistency across the different research communities.

As a part of the 3D-Bioinfo Community, we plan to hold regular meetings and workshops and web conferences, to informally discuss progress and help identify problems that can be addressed collectively. Unlike other 3D-Bioinfo Activities, Activity IV involves a relatively new community that is less well established and will require organising workshops to encourage collaboration and to enable updating of tool catalogues and ontologies. As with the other 3D-Bioinfo Activities, we will coordinate organisation of the workshops

with the ELIXIR's training portal TeSS where appropriate. The first workshop of the Activity IV is going to take place in May 2020.

Future 3D-Bioinfo activities

The above mentioned themes will not only form the initial focus for 3D-Bioinfo but the steering committee will actively monitor the emergence of new technologies and/or new research fields relevant for bioinformatics approaches, which then can be fostered further as new activities. For example, in the field of protein design the overarching aim is to enable completely rational design of proteins with customized biological functions e.g. novel biocatalysts for Green Chemistry to meet sustainability and environmental challenges. In order to foster new developments focused courses/workshops will be organised on such topics. For example, a course or workshop on using biocomputing to understand and engineer biocatalysis is being planned. 3D-Bioinfo will continuously seek to integrate biocomputational efforts with experimental studies in order to systematically generate, test and critically assess new hypotheses on the fundamental properties of highly active enzymes and binding proteins. This would very much increase our quantitative understanding and enhance the capabilities for the rapid generation of binders, inhibitors and biocatalysts for a range of applications in research, technology and medicine.

Interaction of 3D-Bioinfo with other research communities

Alignment with the ELIXIR platforms

All the above 3D-Bioinfo Activities will engage with the ELIXIR platforms as described below.

Interoperability platform – The outcomes of our projects must be easy to discover, to access and to integrate into users' pipelines. This necessitates the use of standardised file formats, metadata, vocabularies and identifiers. We plan to include our resources in FAIRsharing and Identifiers.org. For all Activities we will organise community workshops to develop data exchange and retrieval standards to improve compliance with FAIR principles. Participating teams will also adopt BioSchemas⁶⁹, a European led initiative. For example, different community-wide standards for evaluating predicted models of proteins and protein complexes would be integrated to promote community-wide use. FAIR-ification of benchmark datasets will be undertaken. To implement the 3D-Beacons infrastructure, we will implement a common API specification for macromolecular structure data from both experimentally determined and predicted models. Where possible, the services and tools will also be linked via workflows using common workflow language to help with interoperable workflow software development.

Data platform – We will link key structural bioinformatics data resources to drive the use and re-use of data. For example, data from five UK based structure prediction resources have already been integrated via Genome3D, and ELIXIR implementation studies are already supporting further integration of the data in Genome3D with data from SWISS-MODEL,

developed by the Swiss node. In addition, Activity I will be responsible for the integration of data on known and predicted functional sites, from a large number of participating European groups, in PDBe-KB. Information on the structural impacts of genetic variations predicted by multiple groups will also be integrated and novel visualization strategies for presenting this integrated data will be developed. These will need to clearly distinguish between experimentally known and predicted data. Activity II will be responsible for integrating various benchmark datasets on predicted protein complexes and assemblies, and on experimentally determined complexes annotated with data from other sources (in close coordination with Activity I). Activity III will also integrate benchmark datasets. For example, we will establish Open Access benchmarks sets under FAIR principles, for assessing structure-based drug design applications. This must be done in a robust, sustainable and scalable data ecosystem, allowing the use and re-use of the data, in line with the ELIXIR Data Platform goals.

Tools platform – The participating tools and resources will be registered in BioTools to make them discoverable and sustainable. Currently, there are several hundred tools relating to structural bioinformatics registered in BioTools covering a range of themes. Extending the repertoire of structural bioinformatics tools in BioTools will a) ensure reproducibility, b) allow scaling up by working in cloud environments, e.g. EOSC c) make tools widely available and sustainable for non-expert users. Containerization of these tools in BioContainers will support development of complex workflows. We will use the benchmarking infrastructure OpenEBench to assess tools and help methods development. For example, all tools related to Activity I will be registered in BioTools and the developers will have the opportunity to access expertise on containerization; for Activity II, these will incorporate exemplary datasets from CAMEO and CAPRI. Workflows for modeling protein conformational flexibility and for modelling protein assemblies in the context of Cryo-EM structure determination will be designed in collaboration with respectively, BioExcel and Instruct-ERIC. The development of improved tools for validation of nucleic acid models in Activity IV feeds directly into this platform and all new methods will be registered with BioTools.

Compute platform – The ELIXIR Authentication & Authorisation Infrastructure (ELIXIR-AAI) which connects to other European AAI initiatives like EGI-CheckIn, INSTRUCT ARIA, will be adopted to support depositions. We will link with the compute platform activities to address scalability of the underlying infrastructure for data transfer as well as data access. For example, access to the ELIXIR compute infrastructure and to the European Open Science Cloud resources (EOSC-Hub) will be explored, to enable large-scale assessment of predicted models of protein assemblies in CAPRI prediction rounds, and to disseminate software tools and web-services. Similarly, groups providing large-scale protein structure predictions and variant impacts will seek to benefit from access to the ELIXIR compute infrastructure. We will adopt ELIXIR Authentication & Authorisation Infrastructure (ELIXIR-AAI) to support deposition of ligand-protein

complexes or benchmark results into our future infrastructure. We also need to provide an easy way to store and synchronise our datasets and users' benchmarks results across ELIXIR and other e-Infrastructures.

Training platform – PDBE-KB and participating data resources will work to add training workflows to the **TeSS portal**. As mentioned already, ELIXIR-UK funding has already supported preliminary work on these workflows involving collaborations between multiple partners. **Proteopedia**, which is being developed in collaboration between the Israeli node and PDBE at the hub, will also be a valuable mechanism for training and outreach (see **Figure 4**). Connections with existing initiatives such as the **BioExcel Knowledge Resource Center** will be established. The BioExcel knowledge resource center is a repository for computational biomolecular training resources. The resources are primarily online based, such as tutorials, online courses and videos but also include face-to-face events.

With regards to protein ligand interactions, we will train researchers on the best way to retrieve and use our benchmark

datasets, and promote the usage of preferred benchmark conditions. The Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics will enhance the **Drug Design Workshop**. This is a web-based educational tool⁷⁰ to introduce structure-based computer-aided drug design to the general public. This online workshop constitutes a helpful tool to introduce the concepts of structure-based drug design to young students (15–19 years old) and to the general public. It can also be used as an introductory tool for more advanced students. Several routes of enhancements will be followed, including a better visualization and analysis of the ligand-protein complex, or the selection of new protein targets.

Building on the experience of the CAPRI community in organizing the well-attended **EMBO courses on Integrative of Biomolecular Complexes** (3 editions so far), Activity II will coordinate various training activities and workshops on teaching non-experts how to use protein structure and assembly prediction tools and how to benchmark new prediction methods using various datasets assembled in Activity II. Training workflows will be derived and added to the TeSS

Transfer RNA (tRNA)
(Redirected from TRNA)

tRNA or transfer RNA plays a key role in translation, the process of synthesizing proteins from amino acids in a sequence specified by information contained in messenger RNA^{[1][2]}. During this process, triplets of nucleotides (codons) of the messenger RNA are translated according to the genetic code into one of the 20 amino acids. tRNAs serve as the dictionary in this translation process. They contain a specific triplet nucleotide sequence, the anticodon, and they get attached to a specific (cognate) amino acid. During protein synthesis by ribosomes, tRNAs deliver the correct amino acids through interactions of their anticodon region with the complementary codons on the messenger RNA. Apart from their distinct anticodon regions, different tRNAs have very similar structures, allowing them to all fit into the tRNA-binding sites on the ribosome.

Structure

tRNA is a stable, folded type of RNA present in all living cells. The secondary structure of most tRNA^{[3][4]} is composed of four helical stems (shown in cyan, blue, red and yellow) arranged in a cloverleaf structure and an central four-way junction. **In three dimensions**, tRNA adopts an "L" shape, with the acceptor end (GGP) on one end and the anticodon (ACC) on the other end.

At the acceptor end, amino acid are attached via the **2'-OH or 3'-OH group of the last nucleotide in the acceptor stem**. At the opposite end of the molecule is the anticodon, which pairs with its complementary codon on the messenger RNA.

The two arms of the "L" (**cartoon**) are formed by the **stacking of the acceptor and TΨC-stem** on one side, and of the anticodon and D-stem on the other side. **Tertiary interactions between the TΨC- and D-loop** form the corner of the L-shape and stabilize the structure.

Non-Watson-Crick hydrogen bonding is important in this core (visualize interactively at [DSSR Jmol web interface](#)).

In addition to the four stem loops, tRNA have a variable loop located in between the acceptor and D-stems. This variable loop can be quite small, but for some tRNA such as the serine or leucine-specific tRNA, it can form an additional helix.

Modified nucleotides. Most tRNAs contain modified nucleotides^[5], which are added post-transcriptionally by specific enzymes. Common modifications include isomerisation of uridines into **pseudouridines (Ψ)**, methylation of either the ribose and/or the base, thiolation, reduction of uridines into dihydrouridines (D).

RNA

RNA Base	G	C	U	A	C	G	G	A	G	C	U	C	G	G	A	G	C	U	A	G	
Codon	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
Amino acid	Alanine	Threonine	Glutamate	Leucine	Arginine	Serine	Stop														

Translation of RNA sequence into protein sequence

Standard 2D cloverleaf structure of tRNA. The shown example is phenylalanine-specific tRNA from yeast

Cartoon of a tRNA from yeast (1ehz, backbone trace of the yeast phe-tRNA with base pairing indicated by white cylinders)

± spin ± quality ± labels popup

Export Animated Image

Figure 4. The tRNA page from Proteopedia [<http://proteopedia.org/w/TRNA>]. tRNA plays a key role in translation, the process of synthesizing proteins from amino acids. The two arms of the "L" shaped molecule (cartoon) are formed by the stacking of the acceptor and TΨC-stem.

portal. Activity II will also help coordinate training tasks related to protein structure prediction in the **Meet-U initiative**. This is an innovative pedagogical initiative created in 2016 that teaches MSc students by involving them in real world research projects, with results evaluated by experts in the field during a final scientific symposium. Meet-U is currently implemented as a collaborative course between three universities of Paris/France area: Sorbonne Université (SU/UPMC), Universités Paris-Sud/Paris-Saclay, and Université Paris-Diderot. It is proposed to implement an international version of Meet-U, involving universities linked to ELIXIR nodes across Europe.

There has also been some support from the ELIXIR UK node to develop training workflows in protein structure prediction and variant impact analysis. This has enabled pilot work and the establishment of small-scale training workflows in the ELIXIR TESS registry. For all activities, we will organise training workshops for trainers and users, and add workflows to TeSS where appropriate.

Connection to other communities and European infrastructure initiatives

3D-Bioinfo community users: The 3D-Bioinfo community bridges several infrastructures and their providers as well as users, namely people and tools of structural biology (Instruct-ERIC, iNEXT), cheminformatics (OpenScreen), system biology (ISBE), molecular simulations (BioExcel) and the proposed community for intrinsically disordered proteins (IDP). In addition, the value of structural data in providing insights into the impacts of genetic variations has led to involvement of some of the 3D-BioInfo participating groups with the ELIXIR Rare Disease Community. Similarly, work in all Activities on structural impacts of residue mutations and other research fields of protein engineering and nucleic acid analogues would clearly enable links with the newly emerging ELIXIR Community on Synthetic Biology. The action plan of this community includes the development of new strains with designed metabolic pathways and expression systems. The synergy of the expertise in the 3D-Bioinfo and Synthetic Biology communities will therefore be very important to implement the new biotech applications that can be expected to be generated through the acquired knowledge and expertise generated by the 3D-Bioinfo ELIXIR community.

The tools and services offered by the proposed 3D-Bioinfo Community already have many millions of users per year and the new Activities, described above, will undoubtedly broaden this scope.

As regards potential overlap with Instruct-ERIC, the 3D-Bioinfo community develops tools that go beyond the scope of structural biology and are not covered by the Instruct-ERIC initiatives and efforts. We will work closely with Instruct-ERIC on common areas of interest (e.g. methods for validating experimental protein and nucleic acid structures) and seek support for joint implementations studies.

Connection with industry

Industry and SME involvement – As mentioned already, Activity III (linked to structure-based drug design) is of particular relevance for the pharmaceutical and biotechnology industries, particularly those using computer-aided structure-based drug design programs. Companies involved in the development of scientific software as well as novel bioactive compounds acknowledge the importance of developing benchmarking protocols, and participate in the D3R Grand Challenges by providing undisclosed data. Furthermore, as regards Activity I, PDBe-KB has interactions with OpenTargets platform and provides annotations to major data resources (UniProt, InterPro and Pfam). Development of data standards and distributable infrastructure would further improve accessibility of the added value annotation data for industry users where all four Activities will contribute. We also expect to build up links to the pharmaceutical Industry via the collaborations with BioExcel, and Instruct-ERIC. Future 3D-Bioinfo Activities around protein and enzyme engineering are expected to provide strong links with the industry and it is anticipated that these links will very much strengthen the competitiveness of the developing European biotechnology SMEs.

Integration at a global level

Clearly the ontologies and data exchange formats established and endorsed through 3D-Bioinfo enabled collaborations will be valuable in a global context as well as across Europe. In fact many of the initiatives we will foster such as PDBe-KB, CAPRI and CAMEO already involve other international partners outside Europe. Furthermore, 3D-Bioinfo groups are involved in organising the international community-wide CASP benchmarking of protein structure prediction. We will support and where possible engage in initiatives for global health, for example the Global Alliance for Genomics and Health (GA4GH). We plan to present activities and output from 3D-Bioinfo in special sessions or technology tracks at the European ECCB and international ISMB conferences, the latter of which is held in Europe on alternate years. This will publicise our activities to the wider bioinformatics community, enable us to recruit additional European participants and promote links with other international initiatives.

Conclusions

This proposal capitalises on the extensive European structural bioinformatics expertise. It provides a discussion and action framework for joint development of current and future activities within the European structural bioinformatics community. 3D-Bioinfo will very much foster the interactions with experimental research groups to efficiently reach a better understanding of proteins and their functional properties at a quantitative level. 3D-Bioinfo will also foster focused outreach and training activities. The outlined aims of our planned Activities should facilitate valuable coordination for optimal use of resources and exploit ELIXIRs platforms to good purpose. As demonstrated in our background to this paper and the many tools/resources listed in the BioTools, Europe is

very strong in this area of research and the establishment of the 3D-Bioinfo Community will assist in promoting research interactions, integration of data and tools and standardised practices, making it even stronger. Furthermore, the Community will facilitate the translation of structurally derived insights - in medicine (pharmaceuticals, diagnostics), agriculture, and sustainable production methods. Finally, 3D-Bioinfo

will facilitate collaborations worldwide and promote European research in structural bioinformatics, on a global scale.

Data availability

Underlying data

No data are associated with this article.

References

1. wwPDB consortium: **Protein Data Bank: the single global archive for 3D macromolecular structure data**. *Nucleic Acids Res.* 2019; **47**(D1): D520–D528. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Laskowski RA, MacArthur MW, Moss DS, *et al.*: **PROCHECK: a program to check the stereochemical quality of protein structures**. *J App Cryst.* 1993; **26**: 283–291. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Vaguine AA, Richelle J, Wodak SJ: **SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model**. *Acta Crystallogr D Biol Crystallogr.* 1999; **55**(Pt 1): 191–205. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Todd AE, Orengo CA, Thornton JM: **Evolution of function in protein superfamilies, from a structural perspective**. *J Mol Biol.* 2001; **307**(4): 1113–43. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Murzin AG, Brenner SE, Hubbard T, *et al.*: **SCOP: a structural classification of proteins database for the investigation of sequences and structures**. *J Mol Biol.* 1995; **247**(4): 536–40. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Orengo CA, Michie AD, Jones S, *et al.*: **CATH—a hierarchic classification of protein domain structures**. *Structure.* 1997; **5**(8): 1093–108. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Sali A, Blundell TL: **Comparative protein modelling by satisfaction of spatial restraints**. *J Mol Biol.* 1993; **234**(3): 779–815. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Peitsch MC: **ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling**. *Biochem Soc Trans.* 1996; **24**(1): 274–9. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Jones DT, Taylor WR, Thornton JM: **A new approach to protein fold recognition**. *Nature.* 1992; **358**(6381): 86–9. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Janin J, Bonvin AM: **Protein-protein interactions**. *Curr Opin Struct Biol.* 2013; **23**(6): 859–61. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Lensink MF, Méndez R, Wodak SJ: **Docking and scoring protein complexes: CAPRI 3rd Edition**. *Proteins.* 2007; **69**(4): 704–18. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Wodak SJ, Janin J: **Structural basis of macromolecular recognition**. *Adv Protein Chem.* 2002; **61**: 9–73. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Rodrigues JP, Bonvin AM: **Integrative computational modeling of protein interactions**. *FEBS J.* 2014; **281**(8): 1988–2003. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Miao Z, Westhof E: **RNA Structure: Advances and Assessment of 3D Structure Prediction**. *Annu Rev Biophys.* 2017; **46**: 483–503. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Lorenz R, Bernhart SH, Höner zu Siederdissen C, *et al.*: **ViennaRNA Package 2.0**. *Algorithms Mol Biol.* 2011; **6**: 26. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Cruz JA, Blanchet MF, Boniecki M, *et al.*: **RNA-Puzzles: a CASP-like evaluation of RNA three-dimensional structure prediction**. *RNA.* 2012; **18**(4): 610–25. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Miao Z, Adamiak RW, Blanchet MF, *et al.*: **RNA-Puzzles Round II: assessment of RNA structure prediction programs applied to three large RNA structures**. *RNA.* 2015; **21**(6): 1066–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Miao Z, Adamiak RW, Antczak M, *et al.*: **RNA-Puzzles Round III: 3D RNA structure prediction of five riboswitches and one ribozyme**. *RNA.* 2017; **23**(5): 655–672. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Śledź P, Caffisch A: **Protein structure-based drug design: from docking to molecular dynamics**. *Curr Opin Struct Biol.* 2018; **48**: 93–102. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Gioia D, Bertazzo M, Recanatini M, *et al.*: **Dynamic Docking: A Paradigm Shift in Computational Drug Discovery**. *Molecules.* 2017; **22**(11): pii: E2029. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Rachman MM, Barril X, Hubbard RE: **Predicting how drug molecules bind to their protein targets**. *Curr Opin Pharmacol.* 2018; **42**: 34–39. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Van Gunsteren WF, Berendsen HJ: **Molecular dynamics: perspective for complex systems**. *Biochem Soc Trans.* 1982; **10**(5): 301–5. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Vreede J, Juraszek J, Bolhuis PG: **Predicting the reaction coordinates of millisecond light-induced conformational changes in photoactive yellow protein**. *Proc Natl Acad Sci U S A.* 2010; **107**(6): 2397–402. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Chodera JD, Noé F: **Markov state models of biomolecular conformational dynamics**. *Curr Opin Struct Biol.* 2014; **25**: 135–44. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Chothia C, Lesk AM: **Canonical structures for the hypervariable regions of immunoglobulins**. *J Mol Biol.* 1987; **196**(4): 901–17. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Chothia C, Lesk AM, Levitt M, *et al.*: **The predicted structure of immunoglobulin D1.3 and its comparison with the crystal structure**. *Science.* 1986; **233**(4765): 755–8. [PubMed Abstract](#) | [Publisher Full Text](#)
27. Mouljt J, Fidelis K, Kryshtafovych A, *et al.*: **Critical assessment of methods of protein structure prediction (CASP)-Round XII**. *Proteins.* 2018; **86**(Suppl 1): 7–15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Haas J, Barbato A, Behringer D, *et al.*: **Continuous Automated Model Evaluation (CAMEO) complementing the critical assessment of structure prediction in CASP12**. *Proteins.* 2018; **86**(Suppl 1): 387–398. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Lensink MF, Wodak SJ: **Docking, scoring, and affinity prediction in CAPRI**. *Proteins.* 2013; **81**(12): 2082–95. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Lensink MF, Velankar S, Wodak SJ: **Modeling protein-protein and protein-peptide complexes: CAPRI 6th edition**. *Proteins.* 2017; **85**(3): 359–377. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Waterhouse A, Bertoni M, Bienert S, *et al.*: **SWISS-MODEL: homology modelling of protein structures and complexes**. *Nucleic Acids Res.* 2018; **46**(W1): W296–W303. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Kelley LA, Mezulis S, Yates CM, *et al.*: **The Phyre2 web portal for protein modeling, prediction and analysis**. *Nat Protoc.* 2015; **10**(6): 845–58. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. McGuffin LJ, Street SA, Bryson K, *et al.*: **The Genomic Threading Database: a comprehensive resource for structural annotations of the genomes from key organisms**. *Nucleic Acids Res.* 2004; **32**(Database issue): D196–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Shi J, Blundell TL, Mizuguchi K: **FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties**. *J Mol Biol.* 2001; **310**(1): 243–57. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Pandurangan AP, Stahlhacke J, Oates ME, *et al.*: **The SUPERFAMILY 2.0 database: a significant proteome update and a new webserver**. *Nucleic Acids Res.* 2019; **47**(D1): D490–D494. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Lewis TE, Sillitoe I, Dawson N, *et al.*: **Gene3D: Extensive prediction of globular domains in proteins**. *Nucleic Acids Res.* 2018; **46**(D1): D435–D439. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Mir S, Alhroub Y, Anyango S, *et al.*: **PDBe: towards reusable data delivery infrastructure at protein data bank in Europe**. *Nucleic Acids Res.* 2018; **46**(D1): D486–D492. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

38. Mitchell AL, Attwood TK, Babbitt PC, *et al.*: **InterPro in 2019: improving coverage, classification and access to protein sequence annotations.** *Nucleic Acids Res.* 2019; **47**(D1): D351–D360.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Wilkinson MD, Dumontier M, Aalbersberg IJ, *et al.*: **The FAIR Guiding Principles for scientific data management and stewardship.** *Sci Data.* 2016; **3**: 160018.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Lewis TE, Sillitoe I, Andreeva A, *et al.*: **Genome3D: exploiting structure to help users understand their sequences.** *Nucleic Acids Res.* 2015; **43**(Database issue): D382–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Pieper U, Webb BM, Dong GQ, *et al.*: **ModBase, a database of annotated comparative protein structure models and associated resources.** *Nucleic Acids Res.* 2014; **42**(Database issue): D336–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Ovchinnikov S, Park H, Kim DE, *et al.*: **Protein structure prediction using Rosetta in CASP12.** *Proteins.* 2018; **86**(Suppl 1): 113–121.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Hwang H, Vreven T, Janin J, *et al.*: **Protein-protein docking benchmark version 4.0.** *Proteins.* 2010; **78**(15): 3111–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Pérez-Cano L, Jiménez-García B, Fernández-Recio J: **A protein-RNA docking benchmark (II): extended set from experimental and homology modeling data.** *Proteins.* 2012; **80**(7): 1872–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Vreven T, Moal IH, Vangone A, *et al.*: **Updates to the Integrated Protein-Protein Interaction Benchmarks: Docking Benchmark Version 5 and Affinity Benchmark Version 2.** *J Mol Biol.* 2015; **427**(19): 3031–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Kastriitis PL, Moal IH, Hwang H, *et al.*: **A structure-based benchmark for protein-protein binding affinity.** *Protein Sci.* 2011; **20**(3): 482–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Xue LC, Rodrigues JP, Kastriitis PL, *et al.*: **PRODIGY: a web server for predicting the binding affinity of protein-protein complexes.** *Bioinformatics.* 2016; **32**(23): 3676–3678.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Capella S, Iglesia D, Haas J, *et al.*: **Lessons Learned: Recommendations for Establishing Critical Periodic Scientific Benchmarking.** *BioRxiv.* 2017.
[Publisher Full Text](#)
49. Lensink MF, Wodak SJ: **Score_set: a CAPRI benchmark for scoring protein complexes.** *Proteins.* 2014; **82**(11): 3163–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Bertoni M, Aloy P: **DynBench3D, a Web-Resource to Dynamically Generate Benchmark Sets of Large Heteromeric Protein Complexes.** *J Mol Biol.* 2018; **430**(21): 4431–4438.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Bohnuud T, Luo L, Wodak SJ, *et al.*: **A benchmark testing ground for integrating homology modeling and protein docking.** *Proteins.* 2017; **85**(1): 10–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Prathipati P, Mizuguchi K: **Integration of Ligand and Structure Based Approaches for CSAR-2014.** *J Chem Inf Model.* 2016; **56**(6): 974–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Gaieb Z, Liu S, Gathiaka S, *et al.*: **D3R Grand Challenge 2: blind prediction of protein-ligand poses, affinity rankings, and relative binding free energies.** *J Comput Aided Mol Des.* 2018; **32**(1): 1–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Gaulton A, Hersey A, Nowotka M, *et al.*: **The ChEMBL database in 2017.** *Nucleic Acids Res.* 2017; **45**(D1): D945–D954.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
<https://pubchem.ncbi.nlm.nih.gov/>
55. Norambuena T, Cares JF, Capriotti E, *et al.*: **WebRASP: a server for computing energy scores to assess the accuracy and stability of RNA 3D structures.** *Bioinformatics.* 2013; **29**(20): 2649–2650.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Flores SC, Sherman MA, Bruns CM, *et al.*: **Fast flexible modeling of RNA structure using internal coordinates.** *IEEE/ACM Trans Comput Biol Bioinform.* 2011; **8**(5): 1247–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Schneider B, Božáková P, Necasova I, *et al.*: **A DNA structural alphabet provides new insight into DNA flexibility.** *Acta Crystallogr D Struct Biol.* 2018; **74**(Pt 1): 52–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Černý J, Božáková P, Schneider B: **DNATCO: assignment of DNA conformers at dnatco.org.** *Nucleic Acids Res.* 2016; **44**(W1): W287–W287.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. de Beauchene IC, de Vries SJ, Zacharias M: **Fragment-based modelling of single stranded RNA bound to RNA recognition motif containing proteins.** *Nucleic Acids Res.* 2016; **44**(10): 4565–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Boniecki MJ, Lach G, Dawson WK, *et al.*: **SimRNA: a coarse-grained method for RNA folding simulations and 3D structure prediction.** *Nucleic Acids Res.* 2016; **44**(7): e63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Popena M, Szachniuk M, Antczak M, *et al.*: **Automated 3D structure composition for large RNAs.** *Nucleic Acids Res.* 2012; **40**(14): e112.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Cheng CY, Chou FC, Das R: **Modeling complex RNA tertiary folds with Rosetta.** *Methods Enzymol.* 2015; **553**: 35–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Mattei E, Pietrosanto M, Ferrè F, *et al.*: **Web-Beagle: a web server for the alignment of RNA secondary structures.** *Nucleic Acids Res.* 2015; **43**(W1): W493–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Murshudov GN, Skubák P, Lebede AA, *et al.*: **REFMAC5 for the refinement of macromolecular crystal structures.** *Acta Crystallogr D Biol Crystallogr.* 2011; **67**(Pt 4): 355–367.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Emsley P, Lohkamp B, Scott WG, *et al.*: **Features and development of Coof.** *Acta Crystallogr D Biol Crystallogr.* 2010; **66**(Pt 4): 486–501.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Adams PD, Afonine PV, Bunkóczi G, *et al.*: **PHENIX: a comprehensive Python-based system for macromolecular structure solution.** *Acta Crystallogr D Biol Crystallogr.* 2010; **66**(Pt 2): 213–221.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Joosten RP, Long F, Murshudov GN, *et al.*: **The PDB REDO server for macromolecular structure model optimization.** *IUCr.* 2014; **1**(Pt 4): 213–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Seibel PN, Krüger J, Hartmeier S, *et al.*: **XML schemas for common bioinformatic data types and their application in workflow systems.** *BMC Bioinformatics.* 2006; **7**: 490.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Daina A, Blatter MC, Baillie Gerritsen V, *et al.*: **Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public.** *J Chem Educ.* 2017; **94**(3): 335–344.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:



Version 1

Reviewer Report 11 June 2020

<https://doi.org/10.5256/f1000research.22602.r63105>

© 2020 Fiser A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Andras Fiser 

Department of Systems and Computational Biology, Albert Einstein College of Medicine, The Bronx, NY, USA

The manuscript of Orengo et al presents the goals of the Elixir initiative in the context of historical achievements in the field of 3D Bioinformatics. It is a conceptual piece to provide guidance to an entire field and therefore I would reflect on that.

‘Computational approaches in biology’ always suffered from an identity problem and I believe this manuscript does not help to resolve it and as such it might be a missed opportunity. One major issue is if one approaches computational structural biology as a discipline or a technology. I believe Elixir efforts all about boosting the potential of this discipline but the scope of this effort is still presented rather as a technology that can support other disciplines.

The first sentence of the abstract immediately leaves this question un-answered “Structural bioinformatics provides the scientific methods and tools to analyse, archive, validate, and present the biomolecular structure data generated by the structural biology community.”. By leaving out aspects of “modeling” from the possible contribution, which I believe is a frequent and important aspect of computational structural biology, the authors restrict the activities for retrospective analysis of experimental data, to “bioinformatics”, i.e to “organize, analyze an manipulate data”. And do not make the argument that “modeling”, i.e. gaining new, testable hypothesis and generating new knowledge is also part of this field (e.g. structural modeling of proteins without experimental structures; docking receptors and ligands in so far unseen complexes; predicting new receptor ligand interactions; predicting and modeling protein drug interactions; modeling /simulating protein motions; modeling enzyme kinetics with molecular dynamics or quantum mechanical simulations; etc.).

NIH made an attempt to distinguish between “bioinformatics” and “computational biology”. If I try paraphrase it in a 3D context, 3D-Bioinformatics is: research, development, or application of computational tools and approaches for expanding the use of 3D biological data, including those to acquire, store, organize, archive, analyze, or visualize such data. In contrast to 3D-Computational Biology of biomolecular structures, which is the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of

macromolecular structures.

This review so far was concerned with the first sentence of the Abstract only. The rest of the paper does touch on a number of innovative, activities that generate new knowledge, i.e. a discipline like activity, but at least to this reviewer this is not formulated in the framework enough.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: computational structural biology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 09 June 2020

<https://doi.org/10.5256/f1000research.22602.r63141>

© 2020 Dunbrack R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Roland L. Dunbrack 

Fox Chase Cancer Center, Philadelphia, PA, USA

This opinion article summarizes the activities, both existing and planned, of the 3D-Bioinfo Community within the ELIXIR biological data infrastructure project in Europe. As such, it represents a useful statement of purpose that can be used to guide the efforts of the many participating groups and in the future as a potential means of evaluating the success of those efforts.

The first section of this article (“Major European contributions in structural bioinformatics”) describes the historical impact of European research groups in the field of structural bioinformatics. These contributions are extensive and indisputable but I am not sure that most scientists will find it very interesting. I suppose it is necessary for European funding bodies to hear it, and in the United States we often find ourselves doing the same thing while trying to secure funding for bioinformatics infrastructure like the PDB from the National Institutes of Health and the National Science Foundation. Perhaps this section could be

shortened, or it could briefly mention parallel developments in other parts of the world. For instance, Helen Berman's efforts in transforming and remediating the PDB into a modern bioinformatics infrastructure resource at Rutgers University starting in 1998 and the establishment of the wwPDB in 2003 with PDBe and PDBj deserve some comment.

The second section briefly describes "Major challenges that 3D-Bioinfo will help to address" including proteome-wide protein structure prediction, establishing benchmarks and confidence assessments for structure prediction accuracy, evaluating the impact of sequence variants on protein function and disease, improvements in structure determination by cryo-EM, SAXS, integrative modeling, and other methods that depend on the appropriate use of high-resolution structural data from crystallography, and the prediction of protein-ligand interactions. All of these require significant infrastructure and integration and interoperability of tools and data, and 3D-Bioinfo is well placed to operate in this sphere. All of these make sense, even if they are fairly obvious.

It may be an unpopular opinion, but I don't think protein structure prediction on the proteome scale is such a worthwhile goal, except for organisms that are of significant experimental interest. Because we can make models of millions of proteins from 100s or 1000s of organisms, doesn't mean we should. Most of that data would be unused. The fact that it "remains computationally expensive to build 3D models on a proteome-wide scale" as the article states is not really an issue. The more important issue is making biologically relevant models of proteins – as homo- and heterooligomeric complexes, interacting with ligands and nucleic acids, and in different functional states (e.g., the active and several inactive conformations of kinases).

One challenge that was left out is the validation of experimental structures at the atom/residue level (amino acids, nucleic acid bases, and ligands), and more importantly, their re-refinement with new methods as they are developed. I am a fan of two tools developed by some of the authors on this paper, EDIA for evaluating electron density in X-ray crystal structures on an atom-by-atom basis, and the PDB-REDO database of re-refined crystal structures.

The next section is a general statement of the goals of 3D-Bioinfo: 1) improved interoperable data standards 2) planning for sustainability and integration of data resources; 3) standards, benchmarking, and validation of prediction tools; 4) access to high compute facilities; 5) integration of structural data with other biological data and databases; and 6) training and outreach in bioinformatics. These are all very worthy, if rather broad and general goals.

The next section on "Links between 3D-Bioinfo and the wider European research environment" reads more like a grant progress report and is probably of little interest to the general reader, especially the section on the launch meeting, which could be deleted. This section mentions collaboration with the Protein Structure Initiative (PSI) by some of the current 3D-Bioinfo participants, but the PSI was disbanded in 2015 and this reference should be removed. This section mentions Instruct-ERIC, and it would be helpful to describe what are the similarities and differences in the goals of 3D-Bioinfo and Instruct-ERIC, which may not be that familiar to non-European structural biologists. Instruct-ERIC is more focused on experimental technologies.

Finally, we get to the meat of the matter – the four "Activity" areas: I. Infrastructure for FAIR structural and functional annotations; II. Open resources for sharing, integrating and benchmarking software tools for modelling the proteome in 3D; III. Protein-ligand interactions; IV: Tools to describe, analyze, annotate, and predict nucleic acid structures. (Full disclosure: I am a participant in Activity II).

The first activity (I) is to improve annotations of protein structures, in particular to bring 3rd party annotation resources into the PDBe-KB (knowledge-base) via a standard data exchange format (e.g., json-based formats). These will include functional site annotations, predicted structures, and impact of disease-associated variants on structure. This is appealing to me, since my group generates these kinds of annotations, for example on antibodies, kinases, and protein-protein interactions. Access to these annotations via the PDB would greatly increase the impact of such resources and the depth of annotation of PDB structures. One example that is already in practice is the import of QSBIO and 3Dcomplex annotations for protein assemblies of X-ray structures in the PDB.

Activity II is focused on integrating and benchmarking software for modeling proteins in 3D, including in particular modeling or annotating protein assemblies and conformational flexibility. This aspect of 3D-Bioinfo will include integration of CAMEO and CAPRI, both of which assess structure predictions of proteins or protein complexes, into OpenEBench, which is also part of ELIXIR. It will also involve developing benchmarks for the prediction of the structures of protein assemblies (e.g. for benchmarking docking calculations) and providing a portal for community-derived benchmarks. While there are many such benchmarks, they are not fully integrated into one resource which will likely be productive in the way that CAMEO, CAPRI, and CASP have been. This section could use a more succinct statement of what is missing in existing benchmarks and what 3D-Bioinfo would do to fill the gaps.

Activity III is focused on developing and disseminating benchmarks for modeling protein-ligand complexes, including peptides and macrocyclic compounds, and their affinities. The inclusion of experimentally determined non-active compounds (for the construction of negative data sets) is an important suggestion in the paper. Another goal is to “open the world of structure-based modeling to the broader science community.” Worthy, but easier said than done, and it is not clear what this would look like exactly.

Activity IV is focused on refinement of experimental structures, structural bioinformatics, structure prediction, and benchmarking studies of nucleic acid structures, which, as the authors point out, lag behind comparable efforts on proteins. As with the other Activities, the efforts will be on establishing benchmarks, collecting software tools, and enhancing interoperability. The authors explicitly propose bringing additional research groups outside of 3D-Bioinfo into Activity IV, presumably including those outside of Europe, which would greatly strengthen all of the activities of 3D-Bioinfo.

The paper concludes with a discussion of further interactions of 3D-Bioinfo with other research communities including: (1) ELIXIR “platforms” on Interoperability, Data, Tools, Compute, and Training; (2) European bioinformatics infrastructure initiatives such as those on cheminformatics, systems biology, and intrinsically disordered proteins; (3) connections with industry; and (4) global initiatives. The last of these is given rather short shrift, considering that the efforts of a European 3D-Bioinfo project will not succeed if they don’t include input and adoption by research groups worldwide. In particular, it is surprising not to see any discussion of interactions with the RCSB or PDBj, which are after all components of the World-Wide PDB (wwPDB), along with PDBe.

Very minor:

1. Figure 2: typo, “Uniprot” --> “Uniprot”
2. p. 14: “EMBO courses on Integrative of Biomolecular Complexes” --> “EMBO courses on Integrative Modeling of Biomolecular Complexes”

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: I am a participant in Activity II described in the report. I attended an organizing meeting of 3D-Bioinfo in November 2019 at the EBI, and have attended online meetings of some members of the Activity II group.

Reviewer Expertise: Structural bioinformatics and protein structure prediction

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 22 May 2020

<https://doi.org/10.5256/f1000research.22602.r62621>

© 2020 Tosatto S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Silvio Tosatto 

Department of Biomedical Sciences, BioComputing Laboratory, Padova, I-35121, Italy

The manuscript by Orengo et al. describes the proposed activities of the ELIXIR 3D-Bioinfo user community. This is a useful and necessary contribution to describe the scope and plans of a new ELIXIR user community. The introduction provides a recapitulation of the uses and relevance of structural bioinformatics in different contexts. As the authors note, this is a mature field where several key data resources and initiatives already exist. The manuscript reads well and tries to make convincing arguments for the proposed activities.

Specific comments:

From the scientific point of view:

1. Limits of structural data. Structural data is very important for many purposes, and the authors make this point clearly. However, it has also limits which should be spelled out clearly to avoid the impression of being a panacea. One limit is the availability of experimental data, with some molecules defying structural characterization. A more specific limit is also related to intrinsically disordered proteins (IDPs). This is a different (sub-)field which is not covered by 3D-Bioinfo and has spawned a separate ELIXIR user community with different priorities dictated by the lack of

structural data.

2. Conformational variability. This important aspect is mentioned several times and forms a continuum between fully rigid proteins on one end and IDPs at the other. It is important to clarify this concept in the manuscript. By doing so it also offers areas for further collaboration in ELIXIR across user communities.
3. Proteomics Standards Initiative (PSI). Part of the Human Proteomics Organization (HUPO), it should be referred to as HUPO-PSI. This is the main standardization body in the field and an obvious choice for promoting the standards 3D-Bioinfo aims to establish. As such, it should be introduced in the manuscript and its implications discussed. Of note, at present there is no HUPO-PSI working group in the areas covered by 3D-Bioinfo.
4. Activity 1. The PDBe-KB part is well described and convincing. There is clear potential for synergies on representing IDP data.
5. Activity 2. The description appears somewhat repetitive and its focus may be improved. OpenEBench is a good idea for CAMEO and CARPI, but how can integration be optimally achieved? The conformational modeling portal part is also a bit unclear, especially in light of the overlap with IDPs. A suggestion would be to highlight this as a way to foster collaboration with the IDP user community.
6. Activity 3. The relevance of protein-ligand interactions is out of question. Since this field is of such pharmaceutical relevance, it is also quite mature. It is however not immediately clear what novel benefit 3D-Bioinfo can provide in terms of infrastructure beyond coordination.
7. Activity 4. This is scientifically perhaps the most "novel" part of the proposed activities, as nucleic acid structures have traditionally been a minority in the field. The description seems more typical of a COST Action setup though and the link to ELIXIR should be improved. E.g. how can the ELIXIR services help to achieve the goals of this activity?
8. Future 3D-Bioinfo activities. This section appears somewhat redundant. In the Green Chemistry example it is unclear how this relates to ELIXIR.
9. ISCB. Given the prominent role of at least one main author in the ISCB leadership, this reviewer was expecting a stronger commitment regarding synergies with the society and its COSIs (most notably 3D-SIG). The goals clearly overlap and can benefit from each other.

From the ELIXIR point of view:

1. Platforms. The description of interactions with ELIXIR platforms appears to denote a somewhat cursory knowledge of their activities. The interaction with OpenEBench is well described and convincing. The Data platform description is good for PDBe-KB but after this does not appear related to platform activities. The Compute platform description is also unclear. In all cases, the question is: how will 3D-Bioinfo make convincing use of platform services?
2. Other user communities. A more thorough description of synergies with existing ELIXIR user communities would be welcome. This should also be separated from non-ELIXIR initiatives (e.g. Instruct, iNEXT, etc.). Of note, the IDP user community is already established and not proposed.

Likewise, "Synthetic Biology" should probably be Microbial Biotechnology. The Proteomics community is an easy connection but missing. Other communities, e.g. Plants, may also be relevant. In general, it would be good to have specific items for collaboration listed.

Minor points:

- The manuscript is somewhat redundant and a bit lengthy at 16 pages without references. Streamlining it would improve focus and can contribute to mitigate some of the concerns above.
- The text refers extensively to "Europe" and "European" resources, ca. 60 times throughout. While this is a truism for ELIXIR, it sometimes feels just a bit too much emphasis in its present form.
- Figure 1 contains data for the PDB up to the year 2016 (a), 2017 (b) and 2018 (c). It should be updated and unified with data until 2019.
- When listing COST Actions (p. 8, left column, bottom), a unified format should be used. I.e. either list all titles or none.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Partly

Competing Interests: I know several of the authors personally and/or through ELIXIR. CO, AE and JMH are co-authors on recent collaborative papers with many authors. I am also a current lead of the ELIXIR IDP user community and ExCo of the ELIXIR Data Platform. However, I believe this has not affected my ability to write an objective and unbiased review of the article.

Reviewer Expertise: bioinformatics, computational biology, structural bioinformatics, intrinsically disordered proteins, databases, tools, infrastructure

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 21 May 2020

<https://doi.org/10.5256/f1000research.22602.r63104>

© 2020 Chauvot de Beauchene I et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Sjoerd Jacob De Vries**

RPBS platform, Paris, France

Isaure Chauvot de Beauchene 

LORIA (CNRS, INRIA), University of Lorraine, Nancy, France

Summary

The authors describe the main goals and provide a road-map of the 3D-Bioinfo community, a new Elixir community. A first part states the major contributions and the leading role of many European teams and initiatives in the structural bioinformatics field. Then, the current limitations and challenges faced by this field are discussed, as well as current European initiatives to address them. The core of the paper is the detailed presentation of the goals of the 3D-Bioinfo community, subdivided in activities (or topics) and few main tasks per activity. Details on the implementation of those tasks and on their interconnections are also provided, as well as their complementarity with other European initiatives (especially within ELIXIR).

Major comment

In the paragraph “Develop a knowledge portal to user-friendly bioinformatics and computational tools for modeling conformational flexibility of proteins”, it is surprising to see no mention of any task to define common standards and formats in the description of proteins flexibility.

Minor comments

“However, many challenges still exist. It remains computationally expensive to build 3D models on a proteome-wide scale”

=> Yet this aim is being addressed by the SWISS-MODEL initiative. This assertion should be justified.

“Community will also undertake dedicated educational, training and outreach efforts to facilitate this, bringing new insights and thus facilitating the development of much needed innovative applications e.g. for human health, drug and protein design.”

=> As I understand it, those educational and training efforts are targeting non-informatician structural biologists, and the idea would be to provide them enough insights in 3D-bioinfo for them to foresee possible applications on their system, and apply tools or seek collaboration in 3D-bioinfo. If the training efforts target young 3D-bioinformaticians, then the link with facilitating applications is unclear. The audience could be mentioned here, for clarity.

“Structural bioinformatics tools link sequence and structure data to predict protein functional sites”

=> This sounds like a (restrictive) definition of Structural bioinformatics tools. “[Some] structural bioinformatics tools “ would be more correct.

“As for protein structure prediction, integration of data on sites predicted by different methods will increase both coverage and accuracy.”

=> This assumption could be softened , as the success of this integration is expected but not certain.

“This enables the design of new experiments to study the function of macromolecules as well as rational design of proteins[,RNA ?] and drugs, to modify their function and properties.”

“European structure-based tools have facilitated enzyme reaction mechanism studies by chemists and biochemists.”

=> some references would be welcome here

“The first workshop of the Activity IV is going to take place in May 2020”

=> This should be updated

“The above mentioned themes will not only form the initial focus for 3D-Bioinfo but the steering committee will actively monitor the emergence of new technologies and/or new research fields relevant for bioinformatics approaches, which then can be fostered further as new activities. “

=> why “will not only form the initial focus”, if the other focuses are supposed to emerge in the future?

Cosmetic comments

[] = to add ; { } = to remove

These are small typo or missing comas that are pretty harmless individually, but some can be misleading. And summed up, they impair a fluid reading of this already quite dense paper.

“The technological developments in MX in the previous decade, largely catalysed by the structural genomics initiatives[,] and the on-going revolution in the field of cryo-EM”

“some of the most critical contributions to building protein 3D models from structural templates of homologous proteins[,] happened in Europe in the 1990s”

“Importantly[,] European groups have made major contributions to initiatives “

“In particular, the RNA-Puzzles experiment for evaluation of RNA structure prediction methods, and a series of associated workshops[,] have been introduced in Europe,”

“(i.e. CASP27, CAMEO28 and CAPRI29,30 []) for assessment of the prediction “

“Below we detail[,] the specific thematic aims of each Activity”

“We will bring together the community experts to define data standards for different types of annotations [,] and integration of these annotations using a community-driven data exchange format will facilitate finding,”

“Extend the content of OpenEBench by adding {a} knowledge base integrating software tools for modeling the 3D struc-ture of proteins, protein complexes and assemblies.”

“methods for generating[,] scoring, and ranking models of protein complexes”

“Benchmarking studies performed so far [-] including those carried out in the CSAR52 or D3R Grand Challenge53 (...) - rely on datasets of limited size and diversity (...).”

“Developing benchmarks dataset[s] / Developing [a] benchmarks dataset”

“In order to foster new developments[,] focused courses/workshops will be organised on such topics”

“ exploit ELIXIR{s} platforms “

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Computational molecular modeling, structural bioinformatics

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research